For DLBCL, increased serum IL-18 was correlated with lower CR rates after treatment and decreased OS and DFS [83,84,85], while higher IL-18 tissue expression was characteristic of the more aggressive non-GCB DLBCL subtype [86]. This evidence concerns the gene IL18 and diffuse large B-cell lymphoma.